As a joint initiative of BIOGEN® and regulatory government agency INVIMA, the Pharmacovigilance Program of BIOGEN®, in force since June 2002 to present, aims to ensure the safety of patients, users, doctors, institutions and the community in general, In what concerns with the use of medicines that the company produces or commercializes.
The Pharmacovigilance Program at BIOGEN® constantly monitors the performance of drugs the company maintains in the national market. Its functioning is based on the ability to handle international, national and specifically individual information. Fluid communication with doctors, institutions, patients and INVIMA is necessary to generate actions when a Pharmacovigilance alert is triggered.
The ability to share information is essential for the Pharmacovigilance program to function properly, BIOGEN® encourages and strongly requests that in the event of incidents and adverse related situations to its medicines, immediately informed through the tools that the Laboratory has prepared for this purpose. At the same time INVIMA should be informed, Biogen also shares information with Invima to feed back the investigation of each case reported.
In order for a report to be valid and the investigation can be initiated on time and effectively, all fields of the INVIMA's FOREAM form must be filled out. You can print a copy of the form at the following link (Download form) fill it by hand and send it to our offices at the following address:
Cra 33 Bis # 25B - 68, Bogotá D.C., Colombia.